Dendritic cell therapy with improved outcome in glioma multiforme--a case report.
Malignant gliomas are the most devastating tumors in clinical practice and have poorest survival. Immunological treatment of such patients may likely increase the survival and quality of life. Dendritic cells (DCs), most potent antigen presenting cells in combination with oral chemotherapeutic agents may be tried for patients giving consent to such treatment. We have successfully combined the two therapies in an adult male patient who was on downhill course after being operated on once with post operation chemotherapy and radiotherapy for glioma in the left parietal area. He received five dendritic cell therapy vaccines in combination with oral chemotherapy and responded dramatically having near normal quality of life for an additional five months with this regime, increasing the survival after operation to 11 months. This therapy is continuing with radiological betterment of the lesion. The DCs are matured with antigen extracted from wax embedded tissue at 6th day of culture. We feel that the treatment can be given to more number of patients to establish its efficacy for the dreaded cancer glioblastoma multiforme.
Khan
Jamal A
JA
Microbiology Research Lab, C-38/Sector 20, Noida U.P. 201301, India. cancerclinic2000@yahoo.com
Yaqin
Sharmin
S
D000941:Antigens / Q000737:chemistry; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D001932:Brain Neoplasms / Q000188:drug therapy / Q000628:therapy*; D019496:Cancer Vaccines; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000378:metabolism*; D005910:Glioma / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome
D000941:Antigens; D018906:Antineoplastic Agents, Alkylating; D019496:Cancer Vaccines